Novo Nordisk Cuts Wegovy to US$149/Month in the US What It Signals for Canada In a clear defensive move ahead of generic competition, Novo Nordisk has launched aggressive promotional pricing for Wegovy in the United States offering the oral pill at US$149/month for the 1.5 mg and 4 mg doses through NovoCare and select telehealth providers like Ro and WeightWatchers
This article reviews results from the SOUL (Semaglutide Cardiovascular Outcomes) trial, whose aim was to assess the cardiovascular benefit in oral semaglutide in high-risk individuals
Hypoglycemia (Low Blood Sugar) Since Wegovy increases insulin secretion, there is a risk that your blood sugar can be lowered to dangerous levels
10.1038/nature06639 149 MolitorisB
Clinical trials have shown that WEGOVY leads to greater weight loss compared to other treatments, including Eli Lillys ZEPBOUND , reinforcing its position as a top obesity treatment
BDNF and synaptic plasticity, cognitive function, and dysfunction, in Neurotrophic factors
